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Testing Our Tests:
Surrogate End Points
Versus Driving Patient
Management and Outcomes*
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Boston, Massachusetts
Ideally, in choosing cardiovascular therapeutics for a specific
clinical syndrome, we make evidence-based, outcome-
driven decisions informed by the results of randomized
prospective clinical trials when such information is available.
This type of information forms the most robust basis of
disease-based practice guidelines, which also summarize less
robust types of evidence, such as observational data from
large trials as well as expert opinion.
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When making decisions about choosing a particular
testing modality to assess a disease process in order to make
a clinical management decision, we far less often have such
decisions informed by evidence from randomized clinical
trials. In the case of various types of stress testing, we have
observational data assessing test performance in relation to a
“gold standard,” such as a 50% or more stenosis by angiog-
raphy, as well as numerous studies examining the association
between stress-testing results and subsequent outcomes for
prognosis. In situations where one or more distinct testing
modalities may be used to assess/diagnose/prognosticate the
same disease process, clinicians will often base their choice
of testing modality on their own experience and local
expertise, their impression of the comparative value of the
modalities based on individual studies in the literature, and
now perhaps on emerging meta-analyses comparing perfor-
mance of different testing modalities (1,2). While the
meta-analytic approach overcomes problems associated with
relatively small single-center studies, how to account for
such factors as verification bias and the technical evolution
of testing modalities over time is challenging.
Although less common than in the therapeutic arena,
prospective randomized clinical trials examining different
testing modalities linked to clinical decisions are oc-
casionally undertaken and reported. Studies such as the
Thrombolysis in Myocardial Infarction (TIMI) 2 and the
VANQWISH trials in acute coronary syndromes (3,4),
while often referred to as comparisons of aggressive versus
conservative therapeutic management strategies, are in es-
sence randomized trials of the influence of a choice of initial
testing strategy on subsequent outcome. These trials exam-
ine the strategy of initial referral directly to assessment by
catheterization, with subsequent revascularization based on
anatomic considerations, compared to initial assessment
with stress radionuclide imaging, with subsequent catheter-
ization/revascularization based on physiologic consider-
ations of the extent of inducible ischemia. The results of
these studies comparing initial risk-stratification testing
strategies generally support that initial direct referral to
catheterization will not necessarily result in better long-term
outcomes.
In the clinical syndrome of chronic coronary artery
disease (CAD) accompanied by left ventricular (LV) dys-
function, where issues regarding myocardial viability and
the potential reversibility of left ventricular dysfunction with
revascularization are important drivers of clinical decision
making, several distinct testing modalities have been inves-
tigated extensively over the years. Single-photon emission
computed tomography imaging, using thallium-201 or Tc-
99m–based agents, examines sarcolemmal membrane integ-
rity after tracer delivery via myocardial blood flow (5).
Positron emission tomographic (PET) imaging interrogates
oxidative or glucose metabolism as well as myocardial blood
flow (6), while dobutamine echocardiography examines
regional wall motion and the effect of inotropic stimulation
on contractile reserve (7). The parameters examined by
these testing modalities are characteristic features of viable
but dysfunctional myocardium, a scenario in which clinical
outcome may be improved by revascularization.
Evaluation of each of these testing modalities has fol-
lowed a somewhat stereotypical trajectory over the years.
Early reports tended to examine changes in tracer uptake
itself—for example, with different iterations of thallium-201
imaging protocols, implying evidence of improved identifi-
cation of dysfunctional but viable myocardium (8). The
individual testing modalities were also examined for their
performance characteristics in predicting recovery of re-
gional function after revascularization (8–11). Some authors
suggested that this gold standard is the sine qua non of
myocardial viability assessment, as the aim should always be
to improve function of dyssynergic myocardium (12). Nu-
merous papers have reported on cross-correlative compari-
sons between the testing modalities, examining proportions
of agreement or disagreement. Often in such studies, PET
evidence of preserved metabolic activity is considered the
gold standard comparator. One could question this assump-
tion given the imperfect performance of PET imaging itself
for predicting functional recovery. Changes in global ejec-
tion fraction after revascularization have been less often
studied in this setting as a gold standard, but they consis-
tently have been shown to follow revascularization of a
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certain threshold mass of viable dysfunctional myocardium
(10,13).
What all of these studies have in common is the use of
surrogate end points to evaluate test performance. If one
takes a patient-based or outcome-based perspective, the
major consideration in making a clinical decision for revas-
cularization in the case of chronic CAD, LV dysfunction,
and heart failure is whether the patient will feel better
(assessed in terms of symptoms or functional capacity in
some way) and/or experience an improved natural history
than they might have otherwise without revascularization.
How tightly these patient-based outcomes are tied to the
surrogate end points often used in viability studies is not at
all well established. As has been pointed out, there are many
physiologic outcomes that may follow revascularization and
be associated with improved clinical outcome that do not
necessarily involve recovery of regional or even global
systolic performance (14,15). Such features include im-
provement in diastolic function, improvement in arrhythmic
milieu, prevention of myocardial infarction, and attenuation
of remodeling. Recent data have suggested that survival
after revascularization in the setting of chronic CAD and
LV dysfunction in patients undergoing bypass surgery may
be independent of whether ejection fraction (EF) improves
or not (16). Although some data challenge this (17), much
that we understand about the complex pathophysiology of
chronic ischemic LV dysfunction would suggest that post-
revascularization improvement in measures of systolic per-
formance may be a sufficient but not necessary condition for
improved long-term patient outcome.
This concept calls into question the use of any surrogate
end point for the critical analysis for testing modalities
assessing myocardial viability. For instance, cross-correlative
studies will often show some advantage to one of two
modalities being directly compared. Although differences in
proportions of myocardial segments expressing a certain
amount of tracer uptake, metabolic activity or inotropic
reserve may become statistically significant, the actual total
amount of myocardium per patient, or alternatively the
number of patients with a significant amount of myocar-
dium involved, is usually rather small (15,18). When the
myocardium is segmented into 16 or 20 or even 40 seg-
ments, the number of data points to compare is enlarged
sufficiently to do a careful segmental investigation, but
statistical differences may indeed represent relatively small
amounts of total LV myocardium.
Even carefully performed meta-analyses comparing per-
formance of the different testing modalities may be of
limited generalizability based on the use (by necessity) of
regional functional recovery as the end point of interest (19).
If one believes that regional functional recovery may be a
critically important determinant of outcome, then such
meta-analyses would suggest that using techniques such as
SPECT imaging or dobutamine echocardiography, whose
performance characteristics are not quite as robust as PET,
would lead to less optimal long-term outcomes if used to
drive clinical decisions in this setting. If, however, one takes
the view that the amount of total myocardium represented
by differences in the tests is actually quite small, then one
might expect no difference in long-term outcome no matter
which test is employed. Indeed, a preliminary report of a
meta-analysis examining the relationship between myocar-
dial viability testing and differential outcomes with revascu-
larization and medical therapy reveals no differences be-
tween the testing modalities (20). Thus, the question lingers
whether the relatively small differences between the testing
modalities actually would result in any important differences
in patient-based management or outcomes.
How best do we critically address this dilemma? A study
in this issue of the Journal marks a very important step
forward in this direction. In an elegantly designed trial
meant to address these very questions, Siebelink and col-
leagues (21) have performed a prospective randomized
clinical trial comparing management decisions and out-
comes based on either PET imaging or SPECT imaging in
patients with chronic CAD and LV dysfunction. By the
inclusion criteria, the investigators have focused on patients
in whom such testing is crucial for clinical decisions; that is,
those in whom questions of regional viability will be the
primary drivers of the dichotomous decision to revascularize
or not. Statistically, the study was powered to detect a 20%
difference in long-term outcomes between the PET-driven
and SPECT-driven management, based on observational
trials comparing outcomes with the two testing modalities
(22). Although all patients underwent both PET and
SPECT imaging, each patient was randomized to have
information from only one of the modalities revealed to the
clinical decision-making team, in a polar map format
identifying normal, viable, and infarcted myocardium in a
way that the clinicians could not recognize whether the data
came from the SPECT or PET imaging. Clinical decisions
were made on the basis of the data provided, and the
patients were managed accordingly and followed for long-
term outcomes. The results demonstrated no significant
differences in the proportions of patients sent to revascular-
ization or managed medically; most importantly, there were
no differences in long-term event-free survival between the
groups managed based on results from the different tech-
niques. These data suggest that for the majority of patients
with this clinical syndrome in whom revascularization is
being considered, widely available SPECT imaging tech-
niques, when performed and interpreted with expertise, can
drive patient management decisions and outcomes in a
manner similar to PET imaging.
There are some important features of this study to point
out (21). Only about one-third of the population had very
significant LV dysfunction (EF , 30%), whereas in practice
it is likely that a larger proportion of patients with questions
of viability being considered for revascularization, particu-
larly coronary artery bypass grafting (CABG), fall into this
category. However, the investigators found no difference in
outcomes even among this subgroup of patients with severe
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LV dysfunction using the two different testing modalities.
The PET imaging protocol used by this group of investi-
gators is somewhat out of keeping with standard PET
imaging, in that myocardial blood flow was examined
during pharmacologic stress, with the stress blood flow data
coupled to fluorodeoxyglucose metabolic information at
rest. The information derived from SPECT Tc-99m sesta-
mibi stress/rest imaging was categorized as normal, viable,
or infarcted, and did not take full advantage of the infor-
mation available on the distinction between ischemic, viable
myocardium and viable myocardium without stress-induced
ischemia, a difference that may be important clinically (23).
The patients had a stable clinical syndrome, with the imaging
and decision making taking place over 30 to 40 days; thus,
these data cannot address decision making in more acute
syndromes.
Finally, some might argue that the projected 20% differ-
ence in outcome, which drove the power analysis and
sample size calculations, was too large, given the relatively
small differences between the testing modalities in most
studies. If that is true, then a type II error might have
occurred, indicating that we may be concluding that there is
no difference between test-driven outcomes when in fact
there may be a difference. However, taking the very small
and statistically nonsignificant difference found in the study
and projecting forward, a sample size of close to 20,000
patients would be needed to make these differences statis-
tically significant. Therefore, one might conclude that if a
difference in long-term test-driven outcomes does exist, it is
indeed quite small.
The Siebelink study makes an important contribution to
the literature on myocardial viability and helps inform our
choices of testing modality in a particular clinical scenario.
However, perhaps a more important contribution of this
article is the general example it sets for testing our tests in
the field of cardiovascular diseases. The authors have clearly
demonstrated that carrying out a prospective randomized
clinical trial comparing testing modalities in a rigorous way
for their impact on clinical decision making and outcomes is
feasible. It requires substantial focus on an important
clinical problem by a large multidisciplinary investigative
team, with the patience to gather the appropriate population
and observe their long-term outcomes. It also requires a
belief by the investigative team in the state of clinical
equipoise with regard to the question at hand; that is, that
there is no clear reason to believe that one technique is
clearly superior to another prior to the study.
The study by Siebelink et al. (21) is an important
contribution that will, it is hoped, set a standard for carefully
and critically examining other testing modalities in other
clinical syndromes. At the moment and in the coming years,
debates will continue to simmer regarding the appropriate
use of different testing modalities for screening for early
coronary disease (24), as well as other clinical scenarios such
as testing after myocardial infarction. The study of Siebelink
and colleagues sets an important example that should be
applied to other clinical situations, so that testing our tests
is seen from the template of a patient- and outcome-based
perspective, rather than from a perspective of surrogate end
points.
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